ASPHO is pleased to announce new programs and affiliated meetings in conjunction with our 26th Annual Meeting. You won’t want to miss this exciting expanded meeting.

We are pleased to announce the affiliation of the Pediatric Blood and Marrow Transplant Consortium (PBMTC) meeting with ASPHO’s Annual Meeting. PBMTC will hold its 1-day meeting on Wednesday, April 24, at the Hyatt Regency Miami. The PBMTC meeting features seven symposia and posters. Program details can be found on pages 5–7. Those who opt to attend both the PBMTC and the ASPHO meetings will enjoy a discount on combined registration fees. Refer to the registration form for further information.

ASPHO members interested in developing their knowledge and training skills in palliative care will be interested in the announcement of a new Education in Palliative and End-of-Life Care (EPEC) Pediatrics Curriculum. The curriculum is designed to provide pediatric healthcare providers, especially pediatric oncology specialists, the knowledge and skills needed to provide excellent palliative care to their patients and their families. The EPEC Pediatrics Curriculum includes 17 self-study online modules that can be completed over 10–12 weeks and ideally would be completed prior to attending a face-to-face conference scheduled for Saturday afternoon and Sunday morning, April 27–28, 2013, at the Hyatt Regency Miami, immediately following the ASPHO Annual Meeting. Additional details are available on page 17. Registration is free and can be submitted through the EPEC site at Children’s Hospitals and Clinics of Minnesota. Participation is limited to 50. The EPEC program is funded by the National Cancer Institute of the National Institutes of Health.

In addition to the robust program of clinical topics and original science presentations, this year ASPHO will present a maintenance of certification (MOC) learning session designed to facilitate the completion of an American Board of Pediatrics Lifelong Learning and Self-Assessment module. The MOC program will be offered on Saturday, April 27, at the conclusion of the regular meeting. Advance registration is required.

ASPHO is pleased to announce the formation of three member special interest groups in vascular anomalies, diversity, and palliative care. During the ASPHO Annual Meeting, each of the interest groups will hold open meetings that do not conflict with the regular educational program. You will find descriptions of the meetings within the schedule of session descriptions. Take advantage of this new opportunity to network and collaborate with colleagues.

The ASPHO educational program offers pediatric hematologists/oncologists a concentrated and high-quality continuing medical education (CME) program, covering a broad spectrum of clinical topics and a growing program of original science presentations. In addition to presenting the latest clinical discoveries, the meeting offers you an opportunity to network with colleagues, acquire new skills, meet experts, and advance your career to the next level.

The 2013 meeting will feature

♦ a new advocacy program featuring updates on the ASPHO advocacy agenda as well as a skills-building workshop on using social media to advance advocacy goals
♦ the Presidential Symposium on the Future of Pediatric Oncology
♦ a joint ASPHO and Pediatric Blood and Marrow Transplant Consortium program
♦ eleven symposia and ten workshops
♦ Young Investigator sessions, including a workshop about leadership and communication styles and a symposium discussing the path to promotion
♦ five platform sessions.

Objectives

♦ Comprehend new information in pediatric hematology/oncology, including the latest in basic and clinical research.
♦ Apply knowledge gained in all areas of pediatric hematology/oncology investigation and practice.
♦ Assemble a network of professional colleagues with whom you can solve problems, share experiences, and provide mutual professional support.

“Great meeting! Always a pleasure to attend!”

—2011 Meeting Attendee
Thank You, ASPHO Program Committee

Douglas K. Graham, MD PhD, Chair
University of Colorado Denver
Aurora, CO

Daniel S. Wechsler, MD PhD, Vice Chair
Duke University Medical Center
Durham, NC

Jorge DiPaola, MD, Past Chair
University of Colorado Denver
Aurora, CO

Oussama Abla, MD
Hospital for Sick Children
Toronto, ON, Canada

Denise M. Adams, MD
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH

Patrick Brown, MD
Johns Hopkins Hospital
Baltimore, MD

Valerie Brown, MD PhD
Vanderbilt Children’s Hospital/ Vanderbilt Ingram Cancer Center
Nashville, TN

Mitchell Cairo, MD (PBMTC Liaison)
New York Medical College
Valhalla, NY

Jacqueline N. Casillas, MD MSHS
David Geffen School of Medicine at UCLA
Los Angeles, CA

Sinisa Dojav, MD PhD
Pennsylvania State University College of Medicine
Hershey, PA

Sumit Gupta, MD
Hospital for Sick Children
Toronto, ON, Canada

Caroline A. Hastings, MD
Children’s Hospital of Oakland
Oakland, CA

Neyssa Marina, MD
Stanford University School of Medicine
Palo Alto, CA

Leo Mascarenhas, MD MS
Children’s Hospital Los Angeles
Los Angeles, CA

Kate Mazur, MS BSN PNP
Baylor College of Medicine
Houston, TX

Emily Riehm Meier, MD
Children’s National Medical Center
Washington, DC

David Metto, MD PhD
University of Iowa
Iowa City, IA

Donald William Parsons, MD PhD
Baylor College of Medicine
Houston, TX

Cameron C. Trenor, MD
Children’s Hospital Boston
Boston, MA

Lisa Triche, MSN RN CPNP
University of Texas MD Anderson Cancer Center
Houston, TX

Sarah Vaiselbuh, MD
Staten Island University Hospital
Staten Island, NY

Michael Wang, MD
University of Colorado School of Medicine
Aurora, CO

Donald L. Yee, MD
Baylor College of Medicine
Houston, TX

Peter Zage, MD PhD
Texas Children’s Hospital
Houston, TX

Patrick Zweidler-McKay, MD PhD
University of Texas MD Anderson Cancer Center
Houston, TX

2012–2013 ASPHO Program Committee

CME Credit
The ASPHO 26th Annual Meeting will offer CME credit. Credit will be awarded for those sessions attended and evaluated. A certificate will be issued upon receipt of submission of the evaluation.

ASPHO is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

ASPHO designates this live activity for a maximum of 22.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ASPHO offers its meeting evaluation in an online format. Meeting registrants can access the evaluation by visiting the ASPHO website, ASPHOMeeting.org, and clicking on the Evaluation Form link located on the home page. The online evaluation may be completed during the meeting or after attendees have returned home. Participants will receive their certificate immediately when they submit their evaluations online. We encourage all attendees to complete this evaluation regardless of whether they are seeking CME credits. For more information, visit ASPHOMeeting.org or call 847.375.4716.

Disclosure
It is the policy of ASPHO that the planners, faculty, and providers disclose the existence of any significant financial interests or other relationships they and/or their spouse/partner may have with the manufacturer(s) of any commercial product(s) or services relating to the topics presented in the educational activity. ASPHO requires disclosure of the intent to discuss unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose. It is the responsibility of the Certification and Continuing Education Committee to review potential conflicts of interest as submitted in the disclosure form and resolve such conflicts. Resolving the conflict ensures that the content of the activity is aligned with the interests of the public. Detailed disclosure information will be published in course materials. Learners will also be informed when no relevant financial relationships exist.

Disclaimer
The material presented in this activity represents the opinion of the speakers and not necessarily the views of ASPHO.

Meeting DVDs
ASPHO will offer Annual Meeting attendees session recordings on DVD. Conference attendees will have the opportunity to purchase a DVD when they register for the meeting or in Miami, April 25–27, 2013, at a special discounted rate of $45. After April 27, DVDs will be sold for $250 to members and $350 to nonmembers.

With these DVDs, you will have convenient access to session recordings without long downloads or access codes. Take advantage of this special limited offer when you register or in Miami.
### Schedule at a Glance

#### Wednesday, April 24

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30–3:30 pm</td>
<td>ASPHO Advocacy Update and Workshop</td>
</tr>
<tr>
<td></td>
<td>Advance registration is required.</td>
</tr>
<tr>
<td>2–3:30 pm</td>
<td>Vascular Anomalies Special Interest Group</td>
</tr>
<tr>
<td></td>
<td>Advance registration is required.</td>
</tr>
<tr>
<td>4–5:30 pm</td>
<td>Concurrent Workshops</td>
</tr>
<tr>
<td></td>
<td>(W01) Hematology Consults in the NICU</td>
</tr>
<tr>
<td></td>
<td>(W02) Cardiovascular Disease in Survivors of Childhood Cancer: Novel Insights into Pathophysiology, Screening, and Prevention</td>
</tr>
<tr>
<td>5:45–7:15 pm</td>
<td>Concurrent Workshops</td>
</tr>
<tr>
<td></td>
<td>(W03) Defining Successful Transition Practices for Patients with Hemoglobinopathies and Bleeding Disorders and Cancer Survivors</td>
</tr>
<tr>
<td></td>
<td>(W04) Clinical Genomics for the Pediatric Hematologist/Oncologist</td>
</tr>
<tr>
<td>7:30–9 pm</td>
<td>Corporate Forum Dinner Symposium*</td>
</tr>
<tr>
<td></td>
<td>Division Directors’ Meeting</td>
</tr>
<tr>
<td></td>
<td>Advance registration is required.</td>
</tr>
</tbody>
</table>

#### Thursday, April 25

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30–9 am</td>
<td>Concurrent Workshops</td>
</tr>
<tr>
<td></td>
<td>(W05) Your Personality at Work</td>
</tr>
<tr>
<td></td>
<td>(W06) Updates on Pediatric Stroke and Sinovenous Thrombosis</td>
</tr>
<tr>
<td></td>
<td>(W07) Oncology Band-Aids: Management of Acute Chemotherapy Toxicity</td>
</tr>
<tr>
<td></td>
<td>(S01) 2013: The Future of Pediatric Oncology</td>
</tr>
<tr>
<td>11:30 am–12:30 pm</td>
<td>Concurrent Platform Sessions</td>
</tr>
</tbody>
</table>

#### Friday, April 26

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 am–4:45 pm</td>
<td>Young Investigator Coffee Corner</td>
</tr>
<tr>
<td>7–9 am</td>
<td>Symposia</td>
</tr>
<tr>
<td></td>
<td>(S04) Young Investigator Symposium: Traveling the Path to Promotion—What Is in Your Suitcase?</td>
</tr>
<tr>
<td></td>
<td>(S05) Bah Humbug to the Disbelievers! Vascular Anomalies Are Disorders Needing the Care and Guidance of the Pediatric Hematologist/Oncologist</td>
</tr>
<tr>
<td>9–9:30 am</td>
<td>Break in Exhibit Hall</td>
</tr>
<tr>
<td>9:30–11:30 am</td>
<td>Symposia</td>
</tr>
<tr>
<td></td>
<td>(S06) Treatment of Pediatric Hematologic and Oncologic Disorders in International Resource-Constrained Settings: Practical Strategies and Contemporary Examples</td>
</tr>
<tr>
<td></td>
<td>(S07) New Developments in Histiocytic Disorders</td>
</tr>
</tbody>
</table>

#### Saturday, April 27

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7–8 am</td>
<td>Pediatric Palliative Care Special Interest Group with Breakfast</td>
</tr>
<tr>
<td></td>
<td>Advance registration is required.</td>
</tr>
<tr>
<td>8–9 am</td>
<td>Concurrent Platform Sessions</td>
</tr>
<tr>
<td>9:30–11:30 am</td>
<td>Symposia</td>
</tr>
<tr>
<td></td>
<td>(S10) Photons and Protons—Rays of Hope and Less Despair?</td>
</tr>
<tr>
<td></td>
<td>(S11) Sickle Cell Disease—Hot Topics for the 21st Century</td>
</tr>
<tr>
<td>Noon–2 pm</td>
<td>Noon–2 pm</td>
</tr>
<tr>
<td></td>
<td>(L03) Maintenance of Certification (MOC) Learning Session</td>
</tr>
<tr>
<td></td>
<td>Advance registration is required. Lunch will be served.</td>
</tr>
<tr>
<td></td>
<td>Education in Palliative and End-of-Life Care (EPEC) Pediatrics Curriculum</td>
</tr>
<tr>
<td></td>
<td>For further information, please see page 17.</td>
</tr>
</tbody>
</table>

*For more information on corporate forum symposia, see page 19. See page 5 for Pediatric Blood and Marrow Transplant Consortium program schedule.*
The Pediatric Blood and Marrow Transplant Consortium Educational Program will include a focused day on pediatric bone marrow transplant (BMT) preceding the ASPHO Annual Meeting. The sessions will invigorate the field of pediatric BMT and encourage physicians to learn more about a rapidly advancing field about which they may have limited knowledge. This day focused on pediatric BMT will also allow pediatric hematology/oncology practitioners who do a small amount of pediatric BMT to attend a meeting to which they wouldn’t normally have access.

To register for just the PBMTC program, go to http://2013pbmtc-asphomeeting.eventbrite.com. Contact Laura Hancock with any questions at lhancock@pbmtc.org or 626.241.1619. Discounted registration is offered for those attending both the PBMTC and ASPHO meetings. See the registration form for details.

**Wednesday, April 24, 2013**

**7:30–9 am**

**Author-Attended Poster Session**

8–9:30 am

**B01 Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukemia**

*Michael A. Pulsipher, MD (Moderator)*

There is significant controversy regarding which patients should undergo transplant for acute lymphoblastic leukemia (ALL) in first remission. The risk of relapse after transplant has been correlated with status of remission and level of minimal residual disease present at the time of transplant. New immunological approaches to treating refractory ALL are entering the treatment arena. As these treatments progress, transplant professionals will need to know the latest approaches to direct their patients’ care in a way that offers them the best chance of a cure. By presenting updated data that clarify both indications and outcomes of chemotherapy approaches and transplant for specific patient risk groups as well as new and current data to measure risk, approaches to improving outcomes in high-risk patients, and immunological approaches that can be used both pre- and posttransplant to prevent relapse, we hope to help attendees understand best practices in ALL transplant and when to refer ALL patients, what these patients' chances are of success, and what new treatments may improve patient outcomes.

**Importance of Pre- and Post-MRD**

*Michael A. Pulsipher, MD*

**Indications in CR1 or Lack Thereof**

*Kirk R. Schultz, MD*

**Novel Approaches in Conditioning or Post-AlloSCT to Prevent Relapse**

*Alan S. Wayne, MD*

9:30–11 am

**B02 Alternative Allogeneic Donor Sources in Children with Nonmalignant Hematological Diseases**

*Heather Symons, MD (Moderator)*

New advances have been made in alternative allogeneic donor stem cell transplantation for children with nonmalignant hematological diseases to maximize donor availability and minimize transplant-related complications. The future of allogeneic stem cell transplantation (SCT) in children and adolescents with nonmalignant diseases will require optimizing donor availability while minimizing transplant-related morbidity and mortality with the ultimate goal of improving the efficacy of SCT for nonmalignant hematologic conditions. Session attendees will gain an improved understanding of the advantages and disadvantages of potential alternative donor sources for children and adolescents with nonmalignant diseases that could benefit from SCT.

**Review of Alternative Allografts (MUD, UCBT, Haplo)**

*Heather Symons, MD*

**Alternative Allografts in Patients with Hemoglobinopathies**

*Pietro Sodani, MD*

**Alternative Allografts in Bone Marrow Failure Syndromes in SAA**

*Jakub Tolar, MD*

11 am–12:30 pm

**B03 The Three “I’s” Post-AlloSCT in Children: Immune Reconstitution, Immunization, and Infectious Disease Prophylaxis**

*Julie-An Talano, MD (Moderator)*

Variations of graft sources, the intensity of the conditioning regimens used for pediatric allogeneic stem cell transplant (AlloSCT), and data regarding immune reconstitution, reimmunization, and infectious disease prophylaxis strategies have evolved during the past 10 years. Physicians who care for pediatric patients who have undergone AlloSCT for both nonmalignant and malignant diseases will require more detailed knowledge regarding immune reconstitution, reimmunization, and infectious disease prophylaxis. Attendees of this session will gain an improved understanding of immune reconstitution post-AlloSCT, reimmunization post-AlloSCT, and infectious disease prophylaxis in children and adolescents with nonmalignant and malignant disease who are undergoing AlloSCT.

**Overview by Donor Source**

*Julie-An Talano, MD*

**Infectious Prophylaxis Strategies in Pediatric Allograft Recipients**

*Kieren Marr, MD*

**Vaccination Strategies**

*Michele Hudspeth, MD*

12:30–1 pm

**Lunch**
1–2 pm
(B04) Optimizing Drug Therapy in Stem Cell Transplantation: Focus on Pediatric Pharmacokinetics
Olga Militano, PharmD (Moderator)

Extensive knowledge has been acquired about the pharmacokinetic (PK) features of agents employed in the transplant setting during the past 2 decades. However, defining optimal dose or maximum tolerated dose has been made difficult by extreme PK variability of these drugs, which had led to enthusiasm for PK and pharmacodynamics (PD) studies with the ultimate goal of pharmacokinetically directed therapy (PKDT) to permit optimum chemotherapy and immunotherapy intensity for each individual disease and patient situation. In the use of high-dose chemotherapy and immunosuppressant agents, successful application of PKDT to achieve equivalent “dosimetry” presents several major challenges. These include understanding the metabolism and excretion variables, knowledge of drug-drug interactions, identification of the therapeutically relevant target compound (parent drug versus metabolite), recognition of narrow therapeutic window of cytotoxic/supportive care drugs, and the knowledge of their inherent toxicities. Session attendees will have an improved understanding of the PK and PD variables affecting metabolism of commonly used stem cell transplantation chemotherapy conditioning and immunosuppressant and supportive care agents in children and adolescents with nonmalignant and malignant disease.

Pharmacokinetics/Pharmacodynamics of Agents Used in Stem Cell Transplant Conditioning Regimens and Relevance to Pediatric Clinical Practice
Jeannine S. McCune, PharmD

Current Issues with Therapeutic Drug Monitoring of Immunosuppressants in Pediatric Stem Cell Transplant Recipients
Pamela Jacobson, PharmD

2–3:30 pm
(B05) Role of Allografting in Myeloproliferative Disorders (MPDs) in Children and Adolescents
Evan Shereck, MD (Moderator)

As medical treatments for MPDs improve, there are new questions about which patients should be treated with bone marrow transplantation (BMT) and which should be medically managed. Pediatric hematologists/oncologists must learn for whom and when it is appropriate to consult the BMT team. Pediatric BMT physicians must understand the newest strategies for treating these patients when they proceed to BMT. With this information, attendees will be able to better understand chronic myeloid leukemia, juvenile myelomonocytic leukemia, and myelodysplastic syndrome and recognize the benefits and risks of BMT in MPDs.

Chronic Myelomonocytic Leukemia
Evan Shereck, MD

Juvenile Myelomonocytic Leukemia
Franco Locatelli, MD

3:30–5 pm
(B06) Diagnosis and Management of Hematologic Complications After Allografting In Pediatric Recipients
Roger Giller, MD (Moderator)

Successful outcomes of allogeneic stem cell transplantation in children and adolescents are dependent on both the correction of the underlying malignant or nonmalignant condition and successful supportive care approaches to aid the patient in his or her posttransplant recovery. Hematologic complications, both potential and actual, are among those conditions that require an adequate understanding and knowledge base to diagnose and manage effectively. Session attendees will have an improved understanding of the various unique transfusion medicine issues and hematologic disturbances that can develop following allogeneic hematopoietic stem cell transplant.

Autoimmune Cytopenias
Roger Giller, MD

Thrombotic Microangiopathy (TMA)
Sonata Jodele, MD

Transfusion Medicine Challenges in the Allograft Recipient
Naomi Luban, MD

6–7:30 pm
(B07) Alternative Sources of Allogeneic Cellular Therapy
Mitchell Cairo, MD (Moderator)

New advances have been made in targeted adopted allogeneic cellular therapy, allogeneic stem cell graft engineering, and third-party facilitator allogeneic cellular therapy during the past 10 years. As such, the future of allogeneic stem cell transplantation in children and adolescents with both nonmalignant and malignant diseases will require the use of these therapies. It is necessary to gain an improved understanding of the development and therapeutic use of these therapies in children and adolescents with nonmalignant and malignant disease. Session attendees should be able to understand the risks and benefits of targeted adoptive allogeneic cellular therapy, describe the different methods in allogeneic cellular therapy, and recognize the potential benefits and adverse risks of third-party allogeneic facilitator stem cell therapy.

Targeted Adoptive Cellular Therapy
Stephan Grupp, MD PhD

Allograft Engineering
Colleen Delaney, MD MSc

Third-Party Cellular Therapy
Mitchell Cairo, MD
Pediatric Blood and Marrow Transplant Consortium Educational Program
Being Held in Conjunction with American Society of Pediatric Hematology/Oncology

Faculty

Mitchell Cairo, MD
New York Medical College
Valhalla, NY

Colleen Delaney, MD MSc
Fred Hutchinson Cancer Research Center
Seattle, WA

Roger Giller, MD
Children’s Hospital Colorado
Aurora, CO

Stephan Grupp, MD PhD
Children’s Hospital of Philadelphia
Philadelphia, PA

Inga Hofmann Zhang, MD
Children’s Hospital of Boston
Boston, MA

Michelle Hudspeth, MD
Medical University of South Carolina
Charleston, SC

Pamela Jacobson, PharmD
University of Minnesota
Minneapolis, MN

Sonata Jodele, MD
Cincinnati Children’s Hospital
Cincinnati, OH

Francesca Locatelli, MD
IRCCS Bambino Gesù Children’s Hospital and University of Pavia
Rome, Italy

Naomi Luban, MD
Children’s National Medical Center
Washington, DC

Kieren Marr, MD
Johns Hopkins University
Baltimore, MD

Jeanine S. McCune, PharmD
University of Washington
Seattle, WA

Olga Militano, PharmD
Maria Fareri Children’s Hospital at Westchester Medical Center
Valhalla, NY

Michael A. Pulsipher, MD
Primary Children’s Medical Center/University of Utah
Salt Lake City, UT

Kirk R. Schultz, MD
BC Children’s Hospital/University of BC
Vancouver, BC, Canada

Evan Shereck, MD
Oregon Health and Science University
Portland, OR

Pietro Sodani, MD
IME Foundation, Tor Vergata Hospital
Rome, Italy

Heather Symons, MD
Johns Hopkins University
Baltimore, MD

Julie-An Talano, MD
Medical College of Wisconsin
Milwaukee, WI

Franco Locatelli, MD
IRCCS Bambino Gesù Children’s Hospital and University of Pavia
Rome, Italy

Naomi Luban, MD
Children’s National Medical Center
Washington, DC

Eneida Nemecek, MD MS
Oregon Health and Science University
Portland, OR

Evan Shereck, MD
Oregon Health and Science University
Portland, OR

Heather Symons, MD
Johns Hopkins University
Baltimore, MD

Alan S. Wayne, MD
National Cancer Institute, National Institutes of Health
Bethesda, MD

Planning Committee

Mitchell Cairo, MD
New York Medical College
Valhalla, NY

Allen Chen, MD PhD MHS
Johns Hopkins University
Baltimore, MD

Vicki Fisher, MSN RN CNP CPON
Jazz Pharmaceuticals
Langhorne, PA

Roger Giller, MD
Children’s Hospital Colorado
Aurora, CO

Olga Militano, PharmD
Maria Fareri Children’s Hospital at Westchester Medical Center
Valhalla, NY

Eneida Nemecek, MD MS
Oregon Health and Science University
Portland, OR

Heather Symons, MD
Johns Hopkins University
Baltimore, MD

Julie-An Talano, MD
Medical College of Wisconsin
Milwaukee, WI

Disclaimer

The materials presented in this activity represent the opinions of the speakers and not necessarily the views of ASPHO or PBMTC.

Disclosure

It is the policy of ASPHO that the planners and faculty disclose the existence of any significant financial interest or other relationships they and/or their spouse or partner may have with the manufacturer(s) of any commercial product(s) or services relating to the topics presented in the educational activity. ASPHO requires disclosure of the intent to discuss unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose. It is the responsibility of the Program Committee to review potential conflicts of interest as submitted in the disclosure form and resolve such conflicts. Resolving the conflict ensures that the content of the activity is aligned with the interests of the public. Detailed disclosure information is included in this session information. Learners will also be informed when no relevant financial relationships exist.

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the American Society of Pediatric Hematology/Oncology (ASPHO) and the Pediatric Blood and Marrow Transplant Consortium (PBMTC). The American Society of Pediatric Hematology/Oncology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Society of Pediatric Hematology/Oncology designates this live activity for a maximum of 10.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
**Wednesday, April 24**

1:30–3:30 pm  
**ASPHO Advocacy Update and Workshop**  
Holcombe Grier, MD; Naomi Luban, MD; Mark Del Monte, JD  
This session will describe the federal policy advocacy activities of ASPHO and introduce ASPHO members to advocacy skills, including the use of social media. Faculty will provide an overview of the strategic advocacy plan devised by the ASPHO Advocacy Committee, including a discussion of the priority policy issues affecting pediatric hematologists/oncologists and the children and adolescents for whom they provide care. Advocacy activities planned by the Society to pursue the goals of the strategic plan will be reviewed. The second half of the session will consist of an advocacy skill-building workshop, including both an introduction to federal advocacy for the pediatric hematologist/oncologist and training on how to utilize traditional and social media to advance advocacy goals.  
**Advance registration is required. Limited to 100 attendees.**

2–3:30 pm  
**Vascular Anomalies Special Interest Group**  
Denise Adams, MD, Chair  
The Vascular Anomalies Special Interest Group will hold its first working group meeting to talk about projects and future collaborations, with the aim of identifying standards of practice for treatment of these patients. The meeting is open to interested conference registrants.  
**Advance registration is required.**

4–5:30 pm  
**Concurrent Workshops**

(W01) **Hematology Consults in the NICU**  
Moderators: Pedro A. de Alarcon, MD; Eric Werner, MD  
Although infants in the neonatal intensive care unit (NICU) commonly have hematologic values that fall outside of the established neonatal reference range, neonatologists manage most of these problems. The pediatric hematologist is called for a consult when there are significant signs or symptoms or the hematologic abnormality is severe; few pediatric hematologists spend much time in the NICU. When they are called, they need to know not only the range of disease processes but also factors related to the materno-fetal unit and the rapid developmental changes that affect the baby’s blood. In this workshop, the presenters will use clinical cases to demonstrate an approach to the diagnosis and management of a range of neonatal hematologic disorders.  
**Introduction**  
Pedro A. de Alarcon, MD

(W02) **Cardiovascular Disease in Survivors of Childhood Cancer: Novel Insights into Pathophysiology, Screening, and Prevention**  
Moderator: Saro Armenian, DO MPH  
Childhood cancer survivors are at 15-fold risk of congestive heart failure (CHF) when compared to the general population, in large part because of the dose-dependent association between anthracyclines and CHF. This risk is modified by age at exposure, female gender, and chest irradiation. However, these modifiers fail to explain the wide interindividual variability in risk of CHF, suggesting the existence of genetic susceptibility, an area to be explored in the current workshop (gap #1). Screening for anthracycline-related cardiotoxicity has relied upon serial echocardiography evaluating global systolic function. Often when changes are detected, functional deterioration is mostly irreversible. Screening using novel imaging techniques (echocardiography- and MRI-based) and blood biomarkers may identify heart disease before impairment becomes irreversible (gap #2), setting the stage for interventions to reduce CHF risk (gap #3). This workshop will discuss strategies for integration of pharmacogenomic data, early screening, and prevention in survivors at highest risk for CHF.  
**Introduction**  
Saro Armenian, DO MPH

(W03) **Defining Successful Transition Practices for Patients with Hemoglobinopathies and Bleeding Disorders and Cancer Survivors**  
Moderator: Jane Hankins, MD MS  
Thanks to remarkable progress in treatment and supportive care, the majority of pediatric hematology/oncology patients are now expected to survive into adulthood. Along with improved survivorship comes a need for uninterrupted care as patients with complex illnesses move from adolescence to adulthood. Unfortunately, many adolescent and young adult patients struggle to make the transition from pediatric to adult care, which places them at higher risk for disease-related morbidity and mortality. As pediatric hematology/oncology providers, we have an obligation to prepare patients to successfully transition to adult-centered care. However, there is little agreement in the field regarding which quality indicators should be followed during the transition process and what a successful transition looks like. This workshop will engage participants in a discussion with panelists from both the oncology and hematology fields to help define a successful transition for hematology/oncology patients and the steps to help achieve this goal.
Introduction
Jane Hankins, MD MS

The Backbone of Transition for Pediatric Patients with Chronic Diseases
W. Carl Cooley, MD

The Current Status of Transition for Hemoglobinopathies
Amy E. Sobota, MD MPH

Critical Issues in Transition for Cancer Survivors
Daniel Mulrooney, MD MS

Transitions of Patients with Bleeding Disorders to Adult Care
Vicky R. Breakey, MD

Concluding Remarks and Discussion
Jane Hankins, MD MS; Amy E. Sobota, MD MPH

(W04) Clinical Genomics for the Pediatric Hematologist/Oncologist
Moderator: Michael Link, MD
Genomic microarrays have become a common research tool in oncology, especially the field of pediatric oncology. Single nucleotide polymorphism (SNP) microarrays provide high-resolution, genome-wide information about copy number alterations (CNAs) and loss of heterozygosity (LOH). These genomic microarray studies have been described for nearly every type of cancer seen by pediatric hematologists/oncologists, including neuroblastoma, leukemia, brain tumors, and soft tissue and bone sarcomas. Despite the correlation with clinical features and outcome, SNP microarrays have remained mostly in the realm of research and have not yet been incorporated into clinical care. This interactive workshop will discuss the technology of genomic microarrays, CNA/LOH findings in specific pediatric cancers, barriers to clinical implementation of SNP microarray results, and ways to overcome these challenges to improve the clinical care of our pediatric cancer patients.

Introduction
Michael Link, MD

SNP Microarray and Genomics in Pediatric Cancer
Jaclyn Biegel, PhD

Genomics of Acute Lymphoblastic Leukemia and Ewing’s Sarcoma
Joshua Schiffman, MD

Genomics of Pediatric Brain Tumors
Uri Tabory, MD

Break-Out Sessions

7:30–9 pm
Corporate Forum Dinner Symposium
Seating is limited. For further information, please see page 19.

Division Directors’ Meeting
Advance registration is required.

Thursday, April 25
7:30–9 am
Concurrent Workshops

(W05) Your Personality at Work
Rima Jubran, MD, Joanne M. Hilden, MD, and James Whitlock, MD
“Healthcare delivery, clinical practice, and medical education are all in a state of flux. To deal with the rapid changes and shifting paradigms that are occurring in all three domains, physicians need to demonstrate diverse leadership and management skills. Moreover, although some faculty development programs have targeted leadership skills for healthcare professionals, this area of professional development requires greater attention and further growth” (Steiner, 2011). The first tenet of leadership is to know oneself. This workshop will address aspects of leadership that pertain to personality differences, communication, and conflict management styles.

(W06) Updates on Pediatric Stroke and Sinovenous Thrombosis
Moderator: Emily Riehm Meier, MD
Children with cerebrovascular complications require many hematology consultations, and up-to-date knowledge is necessary for optimal management. The field of pediatric stroke is rapidly growing through collaborative clinical centers and observational studies of risk factors and outcomes. Cerebrovascular disease is heterogeneous in children and has risk factors distinct from those for adult stroke. In children, sickle cell disease, complex cardiac disease, vasculopathy, and thrombophilia are associated with many cerebrovascular events, while a large minority remain idiopathic. The perinatal period presents specific considerations, including distinct pathophysiology, risk factors, management, and outcomes. Fundamental questions including whether to use aspirin or low-molecular-weight heparin for initial management and whether to anticoagulate neonatal sinovenous thrombosis remain controversial. Multicenter trials studying thrombolysis and infectious vasculopathy in pediatric stroke are beginning.

Introduction
Emily Riehm Meier, MD

Arterial Ischemic Stroke
Cameron C. Trenor, MD PhD

Cerebral Sinovenous Thrombosis
Neil A. Goldenberg, MD PhD

Arterial Dissection, Cardiac, and Other Anatomic Considerations
Gabrielle A. DeVéber, MD MHSc

Difficult Cases with Case Discussion
Emily Riehm Meier, MD
ASPHO Educational Program | Thursday, April 25

(W07) Oncology Band-Aids: Management of Acute Chemotherapy Toxicity
Moderator: Leo Mascarenhas, MD MS

The majority of childhood cancers are chemotherapy sensitive, and chemotherapy is almost universally employed in the treatment of most childhood cancers. Acute chemotherapy toxicity is experienced by most patients treated with chemotherapy. In fact, the incidence of grade III and IV acute toxicity is 80% or higher for many treatment protocols commonly employed for treatment. Certain toxicities require modifications of therapy that may result in poorer outcomes. The ASPHO Program Committee has identified several acute complications of chemotherapy as areas in which practicing pediatric hematologists request help and education based on Listserv data (Gap). This workshop will highlight three commonly used drugs (asparaginase, ifosfamide, and methotrexate) and focus on the management of specific acute toxicities, therapeutic interventions, and the impact on continuation of therapy in affected patients as well as possible prevention strategies when indicated.

Introduction
Leo Mascarenhas, MD MS

Acute Toxicity Related to Asparaginase Therapy
Lewis Silverman, MD

Ifosfamide-Related Toxicity
Leo Mascarenhas, MD MS

High-Dose Methotrexate
Brigitte Widemann, MD

Case Presentations and Panel Discussion
Bhakti Mehta, MD MPH

Supported in part by the Pablove Foundation.

9:15–11:15 am
State of the Society, Report from the AAP, and ASPHO Presidential Symposium

(S01) 2013: The Future of Pediatric Oncology
Moderator: A. Kim Ritchey, MD

Advances in our understanding of the biology of childhood cancer and improvements in treatment leading to an 80% cure rate of children have been some of the greatest scientific and clinical stories of the last half century. However, the pace of cure has slowed, and there is uncertainty regarding the plight of those 20% of children who currently do not survive their disease. Recently there has been an explosion of activity that is laying bare the pediatric cancer genome that is likely to directly translate into new therapeutic opportunities in many difficult childhood tumors. What do these discoveries hold for the future of our understanding and treatment of childhood cancer? Clinical trials in childhood cancer have almost uniformly resulted in steady incremental improvement in the cure rate. However, the same clinical research approach that has worked so well in the past is no longer achieving the same results. New paradigms are needed. What does the future hold for clinical research in pediatric oncology? The care of the child with cancer has always been a team effort, with all pediatric hematologists/oncologists able to offer clinical trials to parents and to provide a very high standard of care that was consistent throughout the country—a tremendous achievement! However, there have been major changes in academic medical practice, residency/fellowship regulations, insurance reimbursement, and governmental regulation. It is likely that further changes will be forthcoming. How will these changes influence the practice of pediatric oncology and our ability to care for children and adolescents with cancer?

Sequencing the Genome of Acute Lymphoblastic Leukemia: Insights into Pathogenesis and Therapy
Charles Mullighan, MD MBBS MSc

Improving the Outcome for Children with Cancer: The Costs of Risk Aversion
Peter C. Adamson, MD

A View of the Future of Pediatric Oncology
Joseph V. Simone, MD

11:30 am–12:30 pm
Concurrent Platform Sessions

12:45–2 pm
(L01) One-on-One Young Investigator Career Workshop Lunch
Advance registration is required.

Moderator: Sarah Vaiselbuh, MD

The objective of this luncheon is twofold: (1) to allow fellows and junior faculty members (YIs) to discuss career issues one on one with leaders in the field and (2) to enhance YIs’ knowledge base about ASPHO networking within committees by meeting committee representatives in a small setting.

Fellows and YIs have the opportunity to network with a leader in the field of pediatric hematology/oncology. Experts will be available for career guidance in the following topics: clinical research in hematology, clinical research in oncology, basic science and translational research, issues for clinicians/educators, and career issues specific to foreign medical graduates. Committee representatives from the Professional Development (YI, Certification, Diversity subcommittees), Program, and Membership and Activities Committees, and the Advocacy Task Force will be present. By switching tables YIs can participate in one-on-one career guidance as well as ASPHO committee networking. At the ASPHO committee discussion tables, potential enrollment to become a committee member is available.

(LCH) Clinical Research: Hematology
Zora Rogers, MD; George R. Buchanan, MD

(LCO) Clinical Research: Oncology
William Woods, MD

(LBT) Basic Science/Translational Research
Daniel S. Wechsler, MD PhD; Kathleen M. Sakamoto, MD PhD; Douglas K. Graham, MD PhD

(LCE) Clinician/Educator
Joanne M. Hilden, MD; Caroline A. Hastings, MD

(FMG) Foreign Medical Graduates
Sinisa Dovat, MD PhD
Committee Representatives
Emily Riehm Meier, MD; Guy Young, MD; Sumit Gupta, MD; Theodore Johnson, MD; James Feusner, MD; Naomi Luban, MD

1–2 pm
Non-CME Lunch Session

MIBG Therapy for High-Risk Neuroblastoma
Meaghan Granger, MD

Iodine-131-MIBG is known to be a highly effective therapy for children with relapsed and refractory neuroblastoma and is becoming more prominent in upfront treatment strategies for high-risk patients. This symposium will highlight the types of patients suitable for MIBG therapy in an interactive case discussion format.

Seating for this session is limited. To register for this session, visit www.cookchildrens.org/SpecialtyServices/HematologyOncology/Services/Pages/ASPHO2013.aspx.

This session is supported by Cook Children’s Healthcare System.

2:15–4:15 pm
Symposia

(S02) Novel Therapeutics
Moderator: Sinisa Dovat, MD PhD

Recent advances in the development of novel therapeutics provide new opportunities for targeted treatment of childhood cancer. Future treatment for childhood malignancies will incorporate newly available treatment strategies that avoid some of the toxicities of current therapies (Rossig C, Juergens H, Berdel WE. Pediatr Hematol Oncol. 2011 Oct;28[7]:539–55); (Horton TM, Berg SL. Eur J Pediatr. 2011 May;170[5]:555–9). This symposium will present recent advances in novel therapeutic approaches to different childhood malignancies and viral infections. After completing this activity, participants should be able to (1) summarize recent advances in oncolytic viral therapy, (2) define the key findings from studies of therapy targeting tyrosine kinase in sarcoma, (3) describe the recent advances in gene therapy, and (4) review the advances in targeted therapy for neuroblastoma using difluoromethylornithine (DFMO).

This is a joint PBMTC/ASPHO session.

Introduction
Sinisa Dovat, MD PhD

Oncolytic Viral Therapy
Timothy Cripe, MD PhD

Targeting ODC with DFMO in Neuroblastoma
André Bachmann, PhD MS

Small Molecule Inhibitors
William D. Tap, MD

Democraticizing Gene Therapy: Lowering the Threshold to Infuse Genetically Modified T Cells
Laurence J. N. Cooper, MD PhD

(S03) Evolving Paradigms in Hemophilia—Update on Treatment Approaches
Moderator: Donald L. Yee, MD

Recently completed and ongoing clinical trials in hemophilia have led to significant advances. Such progress includes development of a pipeline of novel agents that may offer greater convenience, safety, and efficacy. Recent studies also identify important risk factors and bleeding-prevention strategies for the disorder's most significant complication, inhibitor development, and highlight meaningful differences between treatment regimens directed at inhibitor eradication. The tantalizing prospect for disease cure offered by gene therapy may finally have passed a critical first step; with sustained conversion of severe hemophilia to a milder phenotype, alternative approaches utilizing other vectors and targets of gene delivery also hold promise. Despite these advances, suboptimal treatment persists for the vast majority of the world's hemophilia population, but projects are underway in developing countries to improve access to care and quality of life. Such efforts are expected to inform best practices worldwide.

Knowledge about hemophilia is evolving rapidly, bringing novel therapeutic approaches that will likely improve access to care, compliance, safety, and efficacy. Providers must incorporate these developments into their knowledge base and practice to optimize patient outcomes.

Introduction
Donald L. Yee, MD

Improving Convenience, Safety, and Efficacy: Design and Development of Novel Agents
Steven Pipe, MD

Inhibitors: Update on Risk Factors, Prevention, and Management
Leonard Valentino, MD

Recent Advances in Gene Therapy for Hemophilia
Paul E. Monahan, MD

Confronting Challenges of Hemophilia Care in the Developing World: A Latin American Perspective
Margareth C. Ozelo, MD PhD

Panel Discussion
This session is supported by Children’s Hospital Los Angeles Hemostasis and Thrombosis Centers.

4:15–4:45 pm
Exhibits Open
Unattended poster viewing.

4:45–5:45 pm
Young Investigator Award Presentations

5:45–6:45 pm
Author-Attended Poster Session A
Odd-numbered posters
**ASPHO Educational Program | Thursday, April 25–Friday, April 26**

5:45–7:30 pm
Grand Opening Reception with Exhibits and Posters

7:30–9 pm
Corporate Forum Dinner Symposium
*Advance registration is required. For further information, please see page 19.*

Fellowship Program Directors’ Meeting
*Advance registration is required.*

Friday, April 26
7 am–4:45 pm
Young Investigator Coffee Corner Opens **NEW**

7–9 am
Symposia

**(S04) Young Investigator Symposium: Traveling the Path to Promotion—What Is in Your Suitcase?**
*Moderator: Sarah Vaiselbuh, MD*

One common denominator on the path to promotion between different institutions is proper preparation by the candidate. Attendees of this symposium will understand the promotion benchmarks used by leadership and ways to define their own value to the division and department. Three areas will be addressed:

1. Candidate preparation for academic promotion (viewpoint of chair of promotion committee)
2. The relative value units (RVUs) rank on a common scale the resources used to provide physician services. These resources include the physician’s clinical work that accounts for the time, technical skills, and effort to provide a service. RVUs have become a tool with which to evaluate a physician’s productivity and salary compensation. Attendees will be introduced to the RVU concept and its challenges.
3. Portfolio building has become complex with the increasing variety of time-consuming activities involved in an academic career. Multiple ways to build an all-inclusive educator’s portfolio will be presented.

**So You Want to Be Promoted?**
*Peter Coccia, MD*

**RVUs: What Is It All About?**
*H. Stacy Nicholson, MD MPH*

**Portfolio Building: Packing Your Suitcase**
*Naomi Luban, MD*

**(S05) Bah Humbug to the Disbelievers! Vascular Anomalies Are Disorders Needing the Care and Guidance of the Pediatric Hematologist/Oncologist**
*Moderator: Denise M. Adams, MD*

Vascular anomaly workshops and symposia at ASPHO have always been very highly attended because of limited knowledge taught to hematologists/oncologists in this area and the increased referral to hematologists/oncologists for these disorders. The topic is noted as a practice gap in our surveys and includes rare tumors such as kaposiform hemangioendotheliomas, angiosarcomas, and other hemangioendotheliomas.

More referrals are being made to hematologists/oncologists for these patients. A better understanding of the pathophysiology is developing. There are now funded clinical trials using treatments most familiar to hematologists/oncologists.

A better understanding of the classification of vascular anomalies is needed to define a phenotype and identify risk stratification. Understanding how this affects decision options and identifying correct therapeutic approaches are necessary.

The most common hematology/oncology consults will be discussed in a tumor board format with some of the world’s experts in vascular anomalies.

**Introduction**
*Denise M. Adams, MD*

**Classification of Vascular Anomalies**
*Denise M. Adams, MD*

**Vascular Anomaly Tumor Board**
*Anita Gupta, MD (Pathologist)*
*Steven Fishman, MD (Surgeon)*
*Manish Patel, DO (Radiologist)*
*Leonardo Brandao, MD (Hematologist)*

**Tumor Board Topics**
- Kaposiform Hemangioendothelioma: Kasabach Merritt Phenomenon, New Treatment Options
- Liver Lesions: Congenital Hemangioma, Infantile Hemangioma, Other Tumors
- Lymphatic Anomalies: Generalized Lymphatic Anomaly/Gorham’s Syndrome
- Complex Vascular Anomalies with Coagulopathy
- Angiosarcoma/Lymphangioasarcoma

**Future Directions**
*Cameron C. Trenor, MD*

9–9:30 am
Break in Exhibit Hall
*Sponsored by St. Jude Children’s Research Hospital*

Exhibits Open

“Very well organized and conducted.”
—2011 Meeting Attendee
9:30–11:30 am
Symposia

(S06) Treatment of Pediatric Hematologic and Oncologic Disorders in International Resource-Constrained Settings: Practical Strategies and Contemporary Examples
Moderator: Sumit Gupta, MD

The major treatment advances for pediatric hematologic and oncologic disorders seen during the past several decades have not translated to children in resource-constrained countries, resulting in significant survival disparities. Recently, however, there have been multiple examples of successful collaborations leading to major improvements in outcome. Such success requires the thoughtful modification of traditional treatment protocols to take into account local resources and capacity, as well as continuous outcome monitoring. In this symposium, the principles of resource-appropriate treatment modification will be explored. This will be followed by concrete contemporary examples of how these principles have been applied, spanning both geographic areas and specific disorders. Finally, the symposium will conclude with a discussion on both the challenges and opportunities available to young investigators who are trying to incorporate an interest in international hematology/oncology into a successful academic career.

Introduction
Sumit Gupta, MD

Modifying COG ALL Therapy in the Dominican Republic
Stephen P. Hunger, MD

Adapting Retinoblastoma Treatment for Low-Income Countries: Accounting for Delay and Abandonment
Guillermo L. Chantada, MD

Optimizing Sickle Cell Disease with Limited Resources
Isaac Odame, MD

Challenges, Opportunities, and Networking in International Medicine as an Academic Career
Panel discussion

(S07) New Developments in Histiocytic Disorders
Moderators: Sarah Vaiselbuh, MD; Oussama Abla, MD

New breakthroughs in understanding the pathophysiology of histiocytic disorders are changing the field and giving hope for newer therapeutic approaches. During this symposium the following topics will be covered: (1) Dr. Bryceson’s research on how defects in cytotoxic lymphocytes are related to immunodeficiency disorders, with a clinical translation to risk stratification for patients with hemophagocytic lymphohistiocytosis (HLH); (2) the rare Rosai Dorfman disease and how collaborative studies are needed to improve understanding of unpredictable disease response and improve outcome (the International Rare Histiocytic Disorders Registry [IRHDR] will be presented as an important tool for data collection); and (3) identification of new mutations in serine/threonine protein kinases in Langerhans cell histiocytosis and their clinical application as a potential target for novel therapy.

Introduction
Sarah Vaiselbuh, MD, and Oussama Abla, MD

Modern Insights in the Molecular Pathogenesis of Hemophagocytic Lymphohistiocytosis (HLH)
Yenan Bryceson, PhD MS

Rosai Dorfman Disease—More Orphan than LCH?
Oussama Abla, MD

Molecular Biology of Langerhans Cell Histiocytosis: V600BRAF as a Target for Therapy?
Carl Allen, MD PhD

Novel Targeted Therapies for LCH
James Whitlock, MD

11:45 am–1:15 pm
Concurrent Workshops

(W08) OPPE, FPPE, RVU, 360 Evaluations: What Does It All Mean for You?
Moderator: Brigitta U. Mueller, MD MHCM

Quality of care is very important to our patients, our employers, and, it is hoped, to all of us. However, how should we measure and evaluate someone’s quality of care? Who should evaluate us? What should be evaluated?

We all have heard of focused professional practice evaluation (FPPE), ongoing professional practice evaluation (OPPE; required for credentialing), relative value units (RVUs; now not just important for billing!), and 360 evaluations, but are we clear about what all of these acronyms actually mean? How these evaluation modalities are being used? What they might mean for our work life and career?

In this workshop we will provide background on these entities and some examples from different colleagues and then try to develop a list of evaluation criteria that we, as pediatric hematologists/oncologists, think are important. Participants will be able to learn from other institutions and gain new ideas on how to implement and use these techniques.

Introduction
Brigitta U. Mueller, MD MHCM

OPPE/FPPE
Jeffrey Hord, MD

Contract Negotiation
Eric Werner, MD

RVUs
Amy L. Billett, MD

Panel Discussion

“This is my first ASPHO meeting as a pediatric fellow and I found all the sessions to be very helpful.”
—2011 Meeting Attendee
(W09) Targeting Rare Pediatric Leukemias  
Moderators: Oussama Abla, MD; Patrick A. Zweidler-Mckay, MD PhD  
Rare cancers, including leukemias such as acute promyelocytic leukemia, juvenile myelomonocytic leukemia, and chronic myeloid leukemia are often overlooked because they represent only a small fraction of the cases we see clinically. However, in these cases biologic information has been acquired that allows for targeted therapy specific to these leukemias, and thus their treatment cannot be extrapolated from generic myeloid leukemias. Through lecture and discussion, workshop attendees will be able to understand the new discoveries that have led to the successful targeting of these leukemias, and they will be better prepared to treat these patients when they arise.

Recent Advances in the Treatment of Acute Promyelocytic Leukemia  
Raul C. Ribeiro, MD

Recent Advances in the Pathogenesis and Treatment of Juvenile Myelomonocytic Leukemia  
Mignon L. Loh, MD PhD

Recent Advances in the Treatment of Chronic Myeloid Leukemia  
Hagop M. Kantarjian, MD

(W10) Challenges in Pediatric Palliative Care  
Moderators: Kate Mazur, MS BSN PNP; Lisa Triche, MSN RN CPNP  
Children with life-limiting illnesses endure many distressing symptoms during their disease trajectory, including both physical symptoms and emotional turmoil. Several of these symptoms are vastly undertreated or unrecognized. Palliative care often takes a back seat when the goal of care continues to be curative and is often delayed until late in the cancer trajectory. Eroneous beliefs of healthcare providers regarding the nature as well as goals of palliative care limit the acceptability and dissemination of these services. Palliative care describes a multidisciplinary approach to the total care of a child, including physical, psychological, and social distress, and is applicable anywhere along the cancer trajectory.

Palliative care symposia presented in recent years have focused on effective pain management techniques as well as the need for education on this topic. This workshop will further expand on symptom management as well as broach new topics that present challenges for many providers.

Introduction  
Kate Mazur, MS BSN PNP; Lisa Triche, MSN RN CPNP

Integrative Palliative Care for Children  
Karen M. Moody, MD

Beyond the Day-1 Talk: Consummate Communication  
Sarah Friebert, MD

Intractable Suffering—Interventions and Ethical Implications  
Justin Baker, MD

Panel Discussion

1:15–2:15 pm  
Lunch in Exhibit Hall  
Author-Attended Poster Session B  
Even-numbered posters

1:15–2:45 pm  
Diversity Special Interest Group

Principles of Effective Networking for Women and Minorities in Pediatric Hematology/Oncology  
Elizabeth Travis, PhD; Theodore Johnson, MD PhD; Sarah Vaiselbuh, MD; Ernest Frugé, PhD; Kathleen M. Sakamoto, MD PhD  
The Diversity SIG will offer an interactive workshop on understanding and addressing the barriers to effective networking for women and minorities that includes effective strategies applicable to a wide range of groups and circumstances. All members are invited to attend this luncheon workshop, but must register in advance for this opportunity to learn and engage in networking with colleagues including representatives of ASPHO leadership.

This session is supported by Stanford University, Division of Hematology/Oncology, Department of Pediatrics.

Overview of the Challenges and Barriers Faced by Women and Minorities in Academic Medicine  
Elizabeth Travis, PhD

Challenges and Barriers Faced by Women and Minorities in Pediatric Hematology/Oncology  
Ernest Frugé, PhD; Kathleen M. Sakamoto, MD PhD

Networking Exercise Using Open-Space Technology  
Sarah Vaiselbuh, MD; Theodore Johnson, MD, PhD

2:15–4:15 pm  
Symposia

(S08) New Advances in the Diagnosis and Treatment of Pediatric and Adolescent Lymphomas  
Moderator: Mitchell Cairo, MD  
New advances have been made in the diagnosis and treatment of pediatric and adolescent lymphomas in the past 5 years, particularly in rare non-Hodgkin lymphoma (NHL) and central nervous system NHL, and use of targeted monoclonal antibody and cellular therapy.

The future diagnosis and treatment of pediatric and adolescent lymphoma will change on the basis of the new information provided during this educational session. An improved understanding of the new treatment modalities and targets in pediatric and adolescent lymphoma will be presented.

Targeted Monoclonal Antibody and Cellular Therapy  
Mitchell Cairo, MD

Rare Pediatric and Adolescent Non-Hodgkin Lymphomas  
Oussama Abla, MD
CNS NHL in Children and Adolescents
Stanton C. Goldman, MD

(S09) An Update on Three-Letter Hematological Diseases (ITP, TTP, HUS)
**Moderator: David Motto, MD PhD**
Recent years have seen considerable progress in the pathophysiology and treatment of the hematologic disorders idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP), as well as with the renal and, often systemic, disorder hemolytic uremic syndrome (HUS). Although HUS shares considerable clinical overlap with TTP, the role of the pediatric hematologist often is unclear in diagnosis and treatment of the disorder. This session will review recent advances regarding the pathophysiology of ITP, TTP, and HUS and will also focus on the current standards of care for all three disorders, with particular emphasis on new and emerging treatment options. Finally, the discussion of HUS will include the point of view of a specialist from Argentina, which has the highest rate of HUS in the world.

Pediatric ITP: Advances in Pathophysiology and Treatment
George R. Buchanan, MD

Infection-Induced HUS: The Argentinian Experience
Eduardo L. Lopez, MD

Congenital and Acquired TTP in Pediatric Patients: Diagnosis and Therapy
James N. George, MD

4:15–4:45 pm
Break in Exhibit Hall
Prizes for Passport Program will be awarded.
Exhibits Open
Unattended poster viewing

4:45–6:45 pm
Business Meeting and Award Presentation
rapy
Distinguished Career Award

6:45–7:30 pm
Awards Reception

Saturday, April 27
7–8 am
Pediatric Palliative Care Special Interest Group
Please join us at the first meeting of the ASPHO Pediatric Palliative Care Special Interest Group. The proposed mission of this group is to accelerate the availability of high-quality palliative care to pediatric oncology patients across the country. Specific objectives include collaboration for palliative care program building; sharing of resources regarding pathways, policies, and procedures; education of faculty, fellows, residents, and medical students; and establishing research priorities and networks.

Advance registration is required.

8–9 am
Concurrent Platform Sessions

9:30–11:30 am
(S10) Photons and Protons—Rays of Hope and Less Despair?
**Moderator: Leo Mascarenhas, MD MS**
Radiation therapy is used extensively in pediatric oncology, particularly in the management of solid tumors including central nervous tumors. The long-term effects of radiation therapy on the developing body and mind are considerable, and careful consideration for its optimal use is paramount (gap 1). ASPHO has not conducted a symposium on this topic in the past.

The use of intensity-modulated radiation therapy (IMRT) with photons during the past 10–15 years and, more recently, the increasing availability of proton therapy (gap 2) as a treatment option in children necessitate the dissemination of their respective indications. Pediatric oncologists are the primary coordinators for the management of childhood cancer patients, and it is imperative they are familiar with the basics of radiation therapy as well as the recent advances that can affect patient outcomes.

Supported in part by Ron and Kim Hegardt.

Radiation Oncology 101 for the Pediatric Oncologist
John A. Kalapurakal, MD FACR

Photon Therapy Including IMRT
Stephanie Terezakis, MD

Proton Therapy
Daniel Indelicato, MD

Case-Based Discussion
Improved supportive care for sickle cell patients has decreased mortality during childhood, which presents today's hematologists with new issues. Models of care have not kept pace with improved survival. For instance, few advances have been made in pain management, even though pain is the hallmark symptom of sickle cell disease (SCD). With decreased childhood mortality and an increasingly complicated care delivery system, a need for a smooth transition from pediatric to adult care has been recognized; however, there is no consensus on the best way to accomplish this. Finally, curative bone marrow transplant is often reserved for sickle cell patients with severe disease. These patients, however, are likely to have received multiple transfusions leading to alloimmunization, which can present unique challenges during transplant.

Introduction
Emily Riehm Meier, MD; Jorge DiPaola, MD

Innovative Pain Management Techniques Including Nonpharmacologic Techniques
Sarah Rebstock, MD PhD MS

Transition of the Adolescent with SCD—Review of the Literature and Practical Advice
Amy E. Sobota, MD MPH

From Transfusion to Transplant: Support for an Alloimmunized SCD Patient
Ross M. Fasano, MD

Noon–2 pm
(L03) Maintenance of Certification Learning Session

This Maintenance of Certification (MOC) Learning Session will feature an American Board of Pediatrics (ABP) Lifelong Learning and Self-Assessment Module; it is intended for those who are enrolled in the MOC process. Learning Sessions are conducted in an interactive group setting and are led by authors or experts in the field of pediatric hematology/oncology.

The 2-hour session will cover the multiple-choice questions in the “2013 Pediatric Hematology-Oncology Self-Assessment.” You must bring your laptop (Wi-Fi will be provided) to enter the answers to each question during the session.

During this session, those enrolled in the ABP MOC program will be able to submit their answers to ABP MOC for scoring to receive MOC Part 2 credit and AMA PRA Category 1 Credits™. The self-assessment is available to enrolled participants through their personal online portfolio from the ABP website, www.abp.org. For additional information about ABP’s MOC program requirements, visit www.abp.org or e-mail MOC@abped.org. Please note that this is not a board review activity; the workshop is designed to facilitate completion of ABP’s Lifelong Learning and Self-Assessment MOC requirement.

Lunch is included. Advance registration is required. The registration fee for this session is $85.

“Enjoyed hearing about a variety of cancers within a single symposia instead of an entire symposia or workshop focused on one specific disease”
—2011 Meeting Attendee

Posters

ASPHO's 26th Annual Meeting will feature two author-attended poster sessions and two unattended sessions. Chosen from a large number of submissions, the posters will represent the best innovations and research in the study and treatment of pediatric hematology/oncology. Poster abstracts selected for presentation at the Annual Meeting will be published online in a searchable PDF and on the Pediatric Blood & Cancer website. This will allow registrants to plan their poster viewing in advance of the meeting. The abstracts are scheduled to be available in March 2013. To search and view the abstracts, visit ASPHO's website at www.ASPHOMeeting.org.
The EPEC curriculum features state-of-the-art knowledge in pain and symptom management, as well as training in the skills required to address key domains for pediatric palliative care. The curriculum is designed to give pediatric healthcare providers, and especially pediatric oncology specialists, the knowledge and skills needed to provide excellent palliative care to their patients and their families. Based on the well-established and proven training methods of EPEC, this curriculum features a high-impact, widely disseminated approach that utilizes a train-the-trainer model.

With knowledge gained through the EPEC Pediatrics Curriculum, physicians and advanced practice registered nurses (APRNs) will be equipped to become trainers who will educate local interdisciplinary teams that provide care to children with cancer and hematological conditions, thus optimizing pediatric palliative care outreach within the pediatric hematology/oncology context.

The EPEC Pediatrics Curriculum includes 17 self-study online modules that can be completed during 10–12 weeks and, ideally, are completed prior to attending a face-to-face conference scheduled for Saturday afternoon and Sunday morning, April 27–28, 2013, at the Hyatt Regency in Miami, immediately following the ASPHO Annual Meeting. This face-to-face conference is designed to offer an opportunity for more in-depth training in the EPEC model of professional education. Participants will receive all training materials in the curriculum upon successful completion of the course.

This course is being offered to MDs and AP/NP RNs in pediatric oncology and other pediatric specialties free of charge to 50 participants. This project is funded by the National Cancer Institute of the National Institutes of Health.

The faculty includes Stefan Friedrichsdorf, MD, Principal Investigator, Children’s Hospitals and Clinics of Minnesota; Joanne Wolfe, MD MPH, Site Principal Investigator, Dana-Farber Cancer Institute and Children’s Hospital, Boston, MA; Linda Emanuel, MD PhD, Site Principal Investigator, EPEC Program, Northwestern University, Chicago, IL; Stacy Remke, LICSW, ACHP-SW Coprincipal Investigator, Children’s Hospitals and Clinics of Minnesota and the University of Minnesota School of Social Work, St. Paul, MN.

For registration information, contact EPEC-Pediatrics at cippc@childrensmn.org.
For additional information, visit www.epec.net.
Oussama Abia, MD  
Hospital for Sick Children  
Toronto, ON, Canada

Denise M. Adams, MD  
Cincinnati Children’s Hospital Medical Center  
Cincinnati, OH

Peter C. Adamson, MD  
Children’s Hospital of Philadelphia  
Philadelphia, PA

Carl Allen, MD PhD  
Baylor College of Medicine/Texas Children’s Cancer Center  
Houston, TX

Saro Armenian, DO MPH  
City of Hope National Medical Center  
Duarte, CA

André S. Bachmann, PhD MS  
University of Hawaii Cancer Center  
Honolulu, HI

Justin Baker, MD  
St. Jude Children’s Research Hospital  
Memphis, TN

Smita Bhatia, MD MPH  
City of Hope National Medical Center  
Duarte, CA

Jaclyn Biegel, PhD  
Children’s Hospital of Philadelphia  
Philadelphia, PA

Amy L. Billett, MD  
Dana-Farber Cancer Institute/Children’s Hospital Boston  
Boston, MA

Leonardo R. Brandao, MD  
Hospital for Sick Children  
Toronto, ON, Canada

Vicky R. Breakey, MD  
Hospital for Sick Children  
Toronto, ON, Canada

Yenan Bryceson, PhD MS  
Karolinska Institutet  
Stockholm, Sweden

George R. Buchanan, MD  
University of Texas Southwestern Medical Center  
Dallas, TX

Mitchell Cairo, MD  
New York Medical College  
Valhalla, NY

Guillermo L. Chantada, MD  
Hospital de Pediatría S.A.M.I.C.  
Prof. Dr. Juan P. Garrahan  
Buenos Aires, Argentina

Peter Coccia, MD  
University of Nebraska Medical Center  
Omaha, NE

W. Carl Cooley, MD  
Crotch Mountain Foundation  
Concord, NH

Laurence J. N. Cooper, MD PhD  
University of Texas MD Anderson Cancer Center  
Houston, TX

Timothy Cripe, MD PhD  
Cincinnati Children’s Hospital Medical Center  
Cincinnati, OH

Pedro A. de Alarcon, MD  
University of Illinois College of Medicine  
Peoria, IL

Gabrielle A. DeVeber, MD MHS  
Hospital for Sick Children  
Toronto, ON, Canada

Jorge DiPaola, MD  
University of Colorado Denver  
Aurora, CO

Sinisa Doval, MD PhD  
Pennsylvania State University College of Medicine  
Hershey, PA

Ross M. Fasano, MD  
Children’s National Medical Center  
Washington, DC

Keren Fernandez, MD  
Children’s Hospital of Illinois  
Peoria, IL

Steven Fishman, MD  
Boston Children’s Hospital  
Boston, MA

Sarah Friebert, MD  
Akrorn Children’s Hospital  
Akrorn, OH

James N. George, MD  
University of Oklahoma Health Sciences Center  
Oklahoma City, OK

Bertil Glader, MD PhD  
Lucile Packard Children’s Hospital at Stanford  
Palo Alto, CA

Neil A. Goldenberg, MD PhD  
University of Colorado Denver  
Aurora, CO

Stanton C. Goldman, MD  
Texas Oncology  
Dallas, TX

Douglas K. Graham, MD PhD  
University of Colorado Denver  
Aurora, CO

Anita Gupta, MD  
Cincinnati Children’s Hospital Medical Center  
Cincinnati, OH

Sumit Gupta, MD  
Hospital for Sick Children  
Toronto, ON, Canada

Jane Hanksins, MD MS  
St. Jude Children’s Research Hospital  
Memphis, TN

Caroline A. Hastings, MD  
Children’s Hospital of Oakland  
Oakland, CA

Joanne M. Hilden, MD  
Children’s Hospital Colorado  
Aurora, CO

Jeffrey Hord, MD  
Akrorn Children’s Hospital  
Akrorn, OH

Stephen P. Hunger, MD  
University of Colorado School of Medicine  
Aurora, CO

Daniel Indelicato, MD  
University of Florida  
Jacksonville, FL

Theodore Johnson, MD PhD  
Georgia Health Sciences University  
Augusta, GA

Rima Jubran, MD  
Children’s Hospital Los Angeles  
Los Angeles, CA

John A. Kalapurakal, MD  
FACR  
Northwestern University  
Chicago, IL

Hapog M. Kantarjian, MD  
University of Texas MD Anderson Cancer Center  
Houston, TX

Kasey Leger, MD  
University of Texas Southwestern Medical Center  
Dallas, TX

Michael Link, MD  
Stanford University  
Palo Alto, CA

Mignon L. Loh, MD PhD  
University of California-San Francisco  
San Francisco, CA

Eduardo L. Lopez, MD  
Hospital Ninos R. Gutierrez  
Buenos Aires, Argentina

Naomi Luban, MD  
Children’s National Medical Center  
Washington, DC

Leo Mascarenhas, MD MS  
Children’s Hospital Los Angeles  
Los Angeles, CA

Kate Mazur, MS BSN PNP  
Baylor College of Medicine  
Houston, TX

Bhakti Mehta, MD MPH  
Children’s Hospital of Los Angeles  
Los Angeles, CA

Emily Riehm Meier, MD  
Children’s National Medical Center  
Washington, DC

Luc Mertens, MD PhD  
Hospital for Sick Children  
Toronto, ON, Canada

Paul E. Monahan, MD  
University of North Carolina  
Chapel Hill, NC

Karen M. Moody, MD  
Montefiore North Hospital  
Bronx, NY

David Mottt, MD PhD  
University of Iowa  
Iowa City, IA

Brigitta U. Mueller, MD MHCM  
Baylor College of Medicine  
Houston, TX

Charles Mullighan, MD MBBS MSc  
St. Jude Children’s Research Hospital  
Memphis, TN

Daniel Mulrooney, MD MS  
St. Jude Children’s Research Hospital  
Memphis, TN

H. Stacy Nicholson, MD MPH  
Oregon Health & Science University  
Portland, OR

Isaac Odame, MD  
Hospital for Sick Children  
Toronto, ON, Canada

Margareth C. Ozelo, MD PhD  
INCTS Hemoctero UNICAMP  
Campinas, Brazil

Manish Patel, DO  
Cincinnati Children’s Hospital Medical Center  
Cincinnati, OH

Steven Pipe, MD  
University of Michigan  
Ann Arbor, MI

Sarah Rebstock, MD PhD MS  
Children’s National Medical Center  
Falls Church, VA

Raul C. Ribeiro, MD  
St. Jude Children’s Research Hospital  
Memphis, TN

A. Kim Ritchey, MD  
Children’s Hospital of Pittsburgh  
Pittsburgh, PA

Zora Rogers, MD  
University of Texas Southwestern Medical Center  
Dallas, TX

Kathleen M. Sakamoto, MD PhD  
Stanford University School of Medicine  
Stanford, CA

Matthew Saxenhouse, MD  
Pediatrie Medical Group  
Charlotte, NC

Joshua Schiffman, MD  
University of Utah  
Salt Lake City, UT

Lewis Silverman, MD  
Dana-Farber Cancer Institute  
Boston, MA

Joseph V. Simone, MD  
Simone Consulting  
Dunwoody, GA

Amy E. Sobota, MD MPH  
Boston Medical Center  
Boston, MA

Uri Tabori, MD  
Hospital for Sick Children  
Toronto, ON, Canada

William D. Tap, MD  
Memorial Sloan-Kettering Cancer Center  
New York, NY

Stephanie Terezakis, MD  
Johns Hopkins School of Medicine  
Baltimore, MD

Cameron C. Treon, MD  
Children’s Hospital Boston  
Boston, MA

Lisa Triche, MSN RN CPNP  
University of Texas MD Anderson Cancer Center  
Houston, TX

Sarah Vaiselbuh, MD  
Staten Island University Hospital  
Staten Island, NY

Leonard Valentino, MD  
Rush University Medical Center  
Chicago, IL

Daniel S. Wechsler, MD PhD  
Duke University Medical Center  
Durham, NC

Eric Werner, MD  
Children’s Hospital of King’s Daughters/Eastern Virginia Medical School  
Norfolk, VA

James Whitlock, MD  
Hospital for Sick Children  
Toronto, ON, Canada

Brigitte Widemann, MD  
National Cancer Institute  
Bethesda, MD

William Woods, MD  
Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta/Emory University  
Atlanta, GA

Donald L. Yee, MD  
Baylor College of Medicine  
Houston, TX

Guy Young, MD  
Children’s Hospital Los Angeles  
Los Angeles, CA

Patrick A. Zweidler-McKay, MD PhD  
University of Texas MD Anderson Cancer Center  
Houston, TX
Corporate Forum Symposia

Independently sponsored corporate forum symposia are offered in conjunction with the ASPHO 26th Annual Meeting. The programs have been reviewed and approved by the 2013 ASPHO Program Committee to ensure that they are relevant to the audience and they do not duplicate the official ASPHO program.

These satellite symposia are open to registrants for the 2013 Annual Meeting at no additional charge, although advance registration is required. See the registration details for each symposium below. Seating is limited and available to those responding on a first-come, first-served basis.

Wednesday, April 24
7:30–9 pm
Corporate Forum Dinner Symposium
New Advances in the Treatment of Transfusional Iron Overload
Thomas D. Coates, MD

This symposium will discuss updates in the diagnosis, monitoring, and treatment of patients with transfusional iron overload. There have been tremendous advances in the past decade in our ability to manage iron overload. This symposium will address practical aspects of monitoring tissue iron burden and the relationship between direct tissue iron measurement and cardiac and endocrine functions as well as strategies regarding the use of combinations of iron chelators.

This activity has been planned and implemented in accordance with the Essentials Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME). Medical Education Resources (MER) is accredited by the ACCME to provide continuing medical education for physicians.

MER designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This symposium is supported by an educational grant from ApoPharma.

There is no registration fee for attending this symposium; however, seating is limited. To register for this symposium, please contact Lori Conwell, CCMEP, Medical Education Resources, at lori@cmepartner.org. Preregistration does not guarantee seating. We recommend arriving at the symposium location early.

Thursday, April 25
7:30–9 pm
Corporate Forum Dinner Symposium
Bleeding and Bruising: A Forum on Diagnosing and Managing Inherited and Acquired Factor Deficiencies
Paula Bolton-Maggs, DM FRCP FRCPath FRCPCH

Numerous disorders can cause abnormal bleeding and bruising in children and adolescents, including qualitative and quantitative platelet disorders, factor disorders, and factor inhibitors. Deficiencies of clotting factors such as fibrinogen, FII, FV, FV+VIII, FVII, FX, FXI, and FXII may be especially challenging to diagnose and treat because of their low prevalence in the general population. In addition, the interpretation of clotting assays is often complex, and the relation between prolongation of coagulation screening tests, plasma levels of deficient factors, and bleeding tendency can vary markedly with each deficiency and among affected patients. This symposium, chaired by renowned hemophilia expert Paula Bolton-Maggs, will provide an opportunity for clinicians to learn more about differential diagnoses, treatment modalities, and management strategies for inherited and acquired factor deficiencies in children and adolescents.

This activity will be planned and implemented in accordance with the Essentials Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Postgraduate Institute for Medicine (PIM), the Cardiovascular & Metabolic Health Foundation, and Educational Concepts in Medicine. PIM is accredited by ACCME to provide continuing medical education for physicians.

PIM designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This symposium is supported through an educational grant from Novo Nordisk, Inc.

There is no registration fee for attending this symposium; however, seating is limited. To register for this symposium, contact Jodi Andrews at jandrews@conceptsinmed.com. Preregistration does not guarantee seating. We do recommend arriving at the symposium location early.

Sunshine Act

The Physician Payment Sunshine Act (Sunshine Act)—Section 6002 of the Patient Protection and Affordable Care Act mandates the disclosure of the National Provider Identifier (NPI) number for any “payment or other transfer of value over $10” given to a physician from any pharmaceutical, device, or biologics manufacturing company. Although final rules are still pending from the Centers for Medicare & Medicaid Services, it seems likely that CME activities will be exempted from reporting, although associated meals will not be exempt.

The Sunshine Act, being implemented in 2013, requires that electronic disclosures be sent to the U.S. Department of Health & Human Services (DHHS). Associations have been requested to help healthcare firms with this compliance by collecting the NPI numbers of their healthcare provider attendees when such a transfer of value from industry to a physician occurs.

To comply with these anticipated rules, ASPHO is collecting the NPI number of its physician conference registrants for reporting purposes. Please note that only industry-supported “transfers of value” (meals, for example) will be collected and reported. Please provide your NPI number where requested on the ASPHO registration form.
Exhibit Schedule

**Thursday, April 25**
8 am–4 pm ............... Exhibit Setup and Registration
5:45–7:30 pm .......... Grand Opening Reception with Exhibits and Posters

**Friday, April 26**
9 am–4:45 pm .......... Exhibit Hours
9–9:30 am ............... Break in Exhibit Hall
1:15–2:15 pm .......... Lunch in Exhibit Hall
4:15–4:45 pm .......... Break in Exhibit Hall
4:45–7:30 pm .......... Exhibit Teardown

New Passport Program for 2013

Win prizes in the Exhibit Hall by visiting participating booths.

ASPHO Thanks 2013 Corporate Members

- AMGEN
- ApoPharma USA INC
- Cook Children’s
- GRIFOLS
- Novo Nordisk
- PURDUE
- SANOFI ONCOLOGY
2013 Exhibitors

American Academy of Pediatrics  
American Society of Clinical Oncology  
ApoPharma  
BTG International Inc.  
Calmoseptine, Inc.  
Cook Children’s Healthcare System  
CureSearch for Children’s Cancer  
Dana-Farber Children’s Hospital Cancer Center  
Gideon’s International  
Grifols  
Novartis Oncology  
Pablove Foundation  
Sigma-Tau Pharmaceuticals, Inc.  
St. Jude Children’s Research Hospital  
Tris Pharma, Inc.  
Walgreens Infusion Services

“Nice collection of presentations that addressed an issue very worthy of discussion though not often showcased at national meetings. Great job!”  
—2011 Meeting Attendee

ASPHO Thanks the Corporate Forum Supporters

ASPHO Thanks Annual Meeting Supporters

ApoPharma  
Cook Children’s.  
novo nordisk®  
Cincinnati Children’s Hospital Medical Center  
Children’s Hospital Los Angeles  
the Pablove Foundation  
St. Jude Children’s Research Hospital  
Stanford School of Medicine  
Ron and Kim Hegardt
Travel Information

Meeting Location
Hyatt Regency Miami
400 SE Second Avenue
Miami, FL 33131

Miami
Offering warmth and sunshine year round, Miami is a diverse city with something for everyone. Enjoy authentic Latin food and dancing, take a stroll along the famous Lincoln Avenue, or soak up the sun and people watch on the hip and trendy South Beach. With places like the Art Deco District, which houses the largest Art Deco collection in the world as well as a unique, multicultural neighborhood, Miami is truly a place for experiencing it all.

Transportation
For current transportation information regarding airline discounts and ground transportation, please visit www.asphomeeting.org.

Housing
ASPHO has negotiated a special conference rate of $189 at the Hyatt Regency Miami. To make your reservation, please call and mention that you are attending the ASPHO Meeting or visit the website for online reservations. The negotiated room rates expire on March 25, 2013, or when the negotiated room block has been filled. After that time, availability will be limited and higher rates may apply.

Hyatt Regency Miami
400 SE Second Avenue
Miami, FL 33131
Reservations: 305.358.1234, 305.374.1728
Rate: $189 single/double
Special Rate Cutoff Date: March 25, 2013
Online Reservations: www.asphomeeting.org

ASPHO Membership Information
ASPHO is the only organization exclusively for and about pediatric hematology/oncology that fosters collaborations to develop optimal treatments for children with blood disorders and cancer.

Why join ASPHO?
When you join ASPHO, you belong to a community of more than 1,800 professionals who share mutual goals, interests, and commitments related to developing optimal treatments for children with blood disorders and cancer. ASPHO is the only professional organization uniquely dedicated to the professional development and interests of sub-specialists in Pediatric Hematology/Oncology.

ASPHO membership provides you with
✦ a member discount of up to $195 on the annual conference registration fee
✦ a monthly subscription to Pediatric Blood & Cancer, the official journal of ASPHO, a source for current, relevant peer-reviewed scientific and clinical research
✦ a forum for presenting research to colleagues and peers
✦ connections to a diverse and collaborative network of peers
✦ a voice for pediatric hematology/oncology policy
✦ access to state-of-the-art education for the subspecialty
✦ leadership and mentoring opportunities
✦ an opportunity to make a difference for your profession, children with blood disorders and cancer, and their families.

Join and register for the annual meeting today! (See the registration form for details.)
### Conference Registration

<table>
<thead>
<tr>
<th>Member Rates</th>
<th>On or before 3/24/13</th>
<th>After 3/24/13</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regular Member</td>
<td>$500</td>
<td>$585</td>
</tr>
<tr>
<td>Allied Member</td>
<td>$295</td>
<td>$380</td>
</tr>
<tr>
<td>Trainee Member</td>
<td>$200</td>
<td>$285</td>
</tr>
<tr>
<td>Emeritus Member</td>
<td>$200</td>
<td>$285</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Joint ASPHO/PBMTC Rates</th>
<th>Nonmember</th>
<th>Nonmember Rates</th>
<th>Nonmember Rate</th>
<th>$695</th>
<th>$780</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$590</td>
<td>$390</td>
<td>$320</td>
<td>$315</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Additional Rates*</th>
<th>Medical Student</th>
<th>$650</th>
<th>$1135</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SIOP Member</td>
<td>$590</td>
<td>$675</td>
</tr>
<tr>
<td></td>
<td>Physician from Developing Country</td>
<td>$210</td>
<td>$295</td>
</tr>
</tbody>
</table>

*Only available by phone, fax, or mail. Verification will be made before registration is processed.

**Subtotal A $**

### Membership Dues

<table>
<thead>
<tr>
<th>Active Member</th>
<th>$365</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allied Member</td>
<td>$150</td>
</tr>
</tbody>
</table>

**Subtotal B $**

### Special Requests

1. I require special assistance. Please contact me. (SA)
2. I will need a vegetarian meal. (SDV)
3. I do not wish to have my name and contact information included in the on-site attendee list. (DIS)

### 4 Easy Ways to Register

- **Mail**: ASPHO Meeting, PO Box 839, Glenview, IL 60025-0839
- **Fax**: 866.585.0477
- **Online**: ASPHOMeeting.org
- **Phone**: 847.375.4716

### Cancellation Policy

All cancellations must be made in writing. A $100 processing fee will be charged for all cancellations postmarked more than 14 days before the event. No refunds will be made under any circumstances on cancellations postmarked after April 10, 2013. ASPHO reserves the right to substitute faculty or to cancel or reschedule sessions because of low enrollment or other unforeseen circumstances. If ASPHO must cancel the entire meeting, registrants will receive a full credit or refund of their paid registration fee. No refunds can be made for lodging, airfare, or any other expenses related to attending the meeting.

### Payment

All funds must be submitted in U.S. dollars.

- Visa
- MasterCard
- Discover
- American Express
- Check

If payment does not accompany this form, your registration will not be processed.

- * Make checks payable to ASPHO. Checks not in U.S. funds will be returned.
- * A charge of $50 will apply to checks returned for insufficient funds.
- * If rebilling of a credit card charge is necessary, a $75 processing fee will be charged.
- * I authorize ASPHO to charge the below-listed credit card an amount reasonably deemed by ASPHO to be accurate and appropriate.

### Session Registration

**Wednesday, April 24**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:30–6 pm</td>
<td>ASPHO Advocacy Update and Workshop (AWK)</td>
</tr>
<tr>
<td>7–9 pm</td>
<td>Vascular Anomalies Special Interest Group (VSIG)</td>
</tr>
</tbody>
</table>

**Thursday, April 25**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>2–3:30 pm</td>
<td>One-on-One Young Investigator Career Workshop Lunch (LO1)</td>
</tr>
<tr>
<td>7–9 pm</td>
<td>Division Directors’ Dinner Meeting (DDM)</td>
</tr>
</tbody>
</table>

**Friday, April 26**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:45 am–1:15 pm</td>
<td>Minority Trainee Mentoring (MTM)</td>
</tr>
<tr>
<td>3:30–5 pm</td>
<td>Young Investigators’ Poster Session (YIPS)</td>
</tr>
</tbody>
</table>

**Saturday, April 27**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 am–11 am</td>
<td>2013 Poster Session (PSS)</td>
</tr>
<tr>
<td>1–3 pm</td>
<td>Oral Paper Session 1 (OPS1)</td>
</tr>
</tbody>
</table>

**Total**

**(A + B + E) = $**
Reasons to Attend the

26th Annual ASPHO Meeting

April 24–27, 2013 ♦ Miami, FL ♦ Hyatt Regency Miami

- Receive up to 22.50 hours of CME credit.
- Network with a diverse and experienced faculty.
- Visit more than 50 exhibitors displaying their products and innovations.
- Take advantage of the Hyatt Regency special conference rate of $189.
- Enjoy all Miami has to offer with fellow ASPHO members.

ASPHOMeeting.org